Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 17/20 | 0.61 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | TNKS | O95271 | 1/20 | 0.47 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1252033 | 0.88 | PARP1 (0.55) | PARP1 | |
| Hydrochloric Acid SCHEMBL1251391 | 0.87 | PARP1 (0.57) | PARP1ADRA1DADRA1AADRA1B | |
| SCHEMBL1249810 | 0.85 | PARP1 (0.68) | PARP1 | |
| SCHEMBL1251622 | 0.85 | PARP1 (0.59) | PARP1ADRA1DADRA1AADRA1B | |
| Hydrochloric Acid SCHEMBL1252446 | 0.84 | DCTPP1 (0.53) | PARP1HTR1ADRD2TNKSTNKS2 | |
| SCHEMBL1252141 | 0.84 | PARP1 (0.59) | PARP1HTR1ADRD2ADRA1DADRA1A | |
| SCHEMBL1251428 | 0.82 | PARP1 (0.57) | PARP1DRD2ADRA1B | |
| Hydrochloric Acid SCHEMBL1249723 | 0.82 | PARP1 (0.59) | PARP1 | |
| SCHEMBL1251424 | 0.82 | PARP1 (0.59) | PARP1 | |
| SCHEMBL1251325 | 0.81 | PARP1 (0.64) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2281818-A1 | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-02-09 | — | — | EP | disclosed |
| US-20080261947-A1 | FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. | 2008-10-23 | — | — | US | disclosed |
| US-7402580-B2 | Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-07-22 | — | — | US | disclosed |
| US-20050085476-A1 | Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-04-21 | — | — | US | disclosed |
| EP-1477175-A1 | FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085476-A1 | Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient | MUSK, RNASE1, DPYD | PARP1 4/4885HTR1A 2209/4885DRD2 2227/4885 |
| US-20080261947-A1 | FUSED PYRIDAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | MUSK, RNASE1, DPYD | PARP1 4/4885HTR1A 2196/4885DRD2 2255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.